p66ShcA promotes malignant breast cancer phenotypes by alleviating energetic and oxidative stress
Kyle Lewis,
Rachel La Selva,
Elias Maldonado,
Matthew G. Annis,
Ouafa Najyb,
Eduardo Cepeda Cañedo,
Stephanie Totten,
Steven Hébert,
Valérie Sabourin,
Caitlynn Mirabelli,
Emma Ciccolini,
Camille Lehuédé,
Luc Choinière,
Mariana Russo,
Daina Avizonis,
Morag Park,
Julie St-Pierre,
Claudia L. Kleinman,
Peter M. Siegel,
Josie Ursini-Siegel
Affiliations
Kyle Lewis
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Department of Biochemistry, McGill University, Montreal, QC, Canada
Rachel La Selva
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Division of Experimental Medicine, McGill University, Montreal, QC, Canada
Elias Maldonado
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Division of Experimental Medicine, McGill University, Montreal, QC, Canada
Matthew G. Annis
Goodman Cancer Institute, McGill University, Montreal, QC, Canada
Ouafa Najyb
Department of Biochemistry, McGill University, Montreal, QC, Canada; Goodman Cancer Institute, McGill University, Montreal, QC, Canada
Eduardo Cepeda Cañedo
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Division of Experimental Medicine, McGill University, Montreal, QC, Canada
Stephanie Totten
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Division of Experimental Medicine, McGill University, Montreal, QC, Canada
Steven Hébert
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada
Valérie Sabourin
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada
Caitlynn Mirabelli
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Division of Experimental Medicine, McGill University, Montreal, QC, Canada
Emma Ciccolini
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Division of Experimental Medicine, McGill University, Montreal, QC, Canada
Camille Lehuédé
Goodman Cancer Institute, McGill University, Montreal, QC, Canada
Luc Choinière
Goodman Cancer Institute, McGill University, Montreal, QC, Canada
Mariana Russo
Goodman Cancer Institute, McGill University, Montreal, QC, Canada
Daina Avizonis
Goodman Cancer Institute, McGill University, Montreal, QC, Canada
Morag Park
Department of Biochemistry, McGill University, Montreal, QC, Canada; Division of Experimental Medicine, McGill University, Montreal, QC, Canada; Goodman Cancer Institute, McGill University, Montreal, QC, Canada; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada
Julie St-Pierre
Department of Biochemistry, Microbiology and Immunology and Ottawa Institute of Systems Biology, University of Ottawa, ON, Canada
Claudia L. Kleinman
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Department of Human Genetics, McGill University, Montreal, QC, Canada
Peter M. Siegel
Department of Biochemistry, McGill University, Montreal, QC, Canada; Division of Experimental Medicine, McGill University, Montreal, QC, Canada; Goodman Cancer Institute, McGill University, Montreal, QC, Canada; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada
Josie Ursini-Siegel
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Department of Biochemistry, McGill University, Montreal, QC, Canada; Division of Experimental Medicine, McGill University, Montreal, QC, Canada; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Corresponding author. Lady Davis Institute for Medical Research 3755 Cote St. Catherine Road, Montreal, QC, H3T 1E2, Canada.
Significant efforts have focused on identifying targetable genetic drivers that support the growth of solid tumors and/or increase metastatic ability. During tumor development and progression to metastatic disease, physiological and pharmacological selective pressures influence parallel adaptive strategies within cancer cell sub-populations. Such adaptations allow cancer cells to withstand these stressful microenvironments. This Darwinian model of stress adaptation often prevents durable clinical responses and influences the emergence of aggressive cancers with increased metastatic fitness. However, the mechanisms contributing to such adaptive stress responses are poorly understood. We now demonstrate that the p66ShcA redox protein, itself a ROS inducer, is essential for survival in response to physiological stressors, including anchorage independence and nutrient deprivation, in the context of poor outcome breast cancers. Mechanistically, we show that p66ShcA promotes both glucose and glutamine metabolic reprogramming in breast cancer cells, to increase their capacity to engage catabolic metabolism and support glutathione synthesis. In doing so, chronic p66ShcA exposure contributes to adaptive stress responses, providing breast cancer cells with sufficient ATP and redox balance needed to withstand such transient stressed states. Our studies demonstrate that p66ShcA functionally contributes to the maintenance of aggressive phenotypes and the emergence of metastatic disease by forcing breast tumors to adapt to chronic and moderately elevated levels of oxidative stress.